“Generics, Get the Facts Straight” - subject of South Africa workshop

29 October 2013
drugs_pills_tablets_big

South Africa’s National Association of Pharmaceutical Manufacturers (NAPM) held a workshop for health care practitioners at the Johannesburg Country Club earlier this month, titled Generics, Get the Facts Straight.

The workshop discussed the manner in which generic medicines were developed and registered in South Africa. One of the arguments given by detractors of generic medicines is that these medicines are not tested in human beings. Professor Jacques Snyman, former head of the department of Clinical Pharmacology at the Steve Biko School of Medicine, described how bioequivalence studies are carried out, He referred to trials which showed overall differences between standards in branded medicines and generic equivalents to be in the region of 3.5%. He also indicated that when most originator companies made improved versions of older drugs, they did not repeat the clinical trials but used bioequivalence to show non-inferiority.

Ulundi Behrtel, an attorney qualified in medical law, spoke on the ethics of prescribing medicine. She pointed out that one of the main aspects of ethics is that a professional person had the responsibility of autonomy in making the best decision for the patient. Patients had a right to be informed and communication was one of the ethical duties of a health care professional. Other considerations such as affordability were secondary to the patient’s interest. She urged the audience to become familiar with the requirements of the HPCSA, the Nursing and Pharmacy Councils when it came to the members’ ethical duties.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics